Kesang Li

1.1k total citations
20 papers, 811 citations indexed

About

Kesang Li is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Kesang Li has authored 20 papers receiving a total of 811 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Immunology. Recurrent topics in Kesang Li's work include CAR-T cell therapy research (5 papers), Circular RNAs in diseases (4 papers) and RNA modifications and cancer (3 papers). Kesang Li is often cited by papers focused on CAR-T cell therapy research (5 papers), Circular RNAs in diseases (4 papers) and RNA modifications and cancer (3 papers). Kesang Li collaborates with scholars based in China, United States and United Kingdom. Kesang Li's co-authors include Hua Jiang, Bizhi Shi, Zonghai Li, Xiaorong Pan, Huiping Gao, Hongyang Wang, Pengfei Zhang, Jing Wu, Jianren Gu and Shengli Yang and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Molecular Cancer.

In The Last Decade

Kesang Li

19 papers receiving 801 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kesang Li China 13 428 364 274 270 99 20 811
Xiuqi Wu China 9 299 0.7× 557 1.5× 108 0.4× 355 1.3× 83 0.8× 13 816
Zachary Rae United States 5 346 0.8× 381 1.0× 231 0.8× 371 1.4× 73 0.7× 7 806
Jizhou Tan China 10 239 0.6× 259 0.7× 110 0.4× 189 0.7× 101 1.0× 17 625
Huajun Jin China 15 321 0.8× 414 1.1× 121 0.4× 238 0.9× 31 0.3× 27 731
Huiping Gao China 12 248 0.6× 616 1.7× 66 0.2× 392 1.5× 192 1.9× 22 889
Christine Alewine United States 18 295 0.7× 517 1.4× 97 0.4× 395 1.5× 18 0.2× 51 1.1k
Mei‐Kuang Chen United States 12 527 1.2× 912 2.5× 131 0.5× 348 1.3× 32 0.3× 24 1.2k
Liman Qiu China 13 311 0.7× 171 0.5× 237 0.9× 157 0.6× 100 1.0× 21 633
Chang Gon Kim South Korea 11 282 0.7× 470 1.3× 99 0.4× 364 1.3× 86 0.9× 15 893
Zhenlong Ye China 13 330 0.8× 593 1.6× 153 0.6× 342 1.3× 13 0.1× 19 909

Countries citing papers authored by Kesang Li

Since Specialization
Citations

This map shows the geographic impact of Kesang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kesang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kesang Li more than expected).

Fields of papers citing papers by Kesang Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kesang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kesang Li. The network helps show where Kesang Li may publish in the future.

Co-authorship network of co-authors of Kesang Li

This figure shows the co-authorship network connecting the top 25 collaborators of Kesang Li. A scholar is included among the top collaborators of Kesang Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kesang Li. Kesang Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wu, Jing, Meng-Xuan Zhu, Kesang Li, Ling Peng, & Pengfei Zhang. (2022). Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer. Cancer Drug Resistance. 5(2). 261–270. 24 indexed citations
3.
Li, Kesang, Yilan Sun, Georgios Giamas, et al.. (2022). Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas. Cancer Gene Therapy. 29(10). 1418–1428. 3 indexed citations
4.
Li, Kesang, S. B. Qian, Mengmeng Huang, et al.. (2021). Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.. American Journal of Translational Research. 13(1). 156–167. 13 indexed citations
5.
6.
Li, Kesang, Liqin Liu, Xiaolu Wang, et al.. (2020). The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma. Biomaterials Science. 9(3). 765–773. 38 indexed citations
7.
8.
Xu, Wen, Kesang Li, Xiaotong Wang, et al.. (2020). Knockdown of lncRNA LINC01234 Suppresses the Tumorigenesis of Liver Cancer via Sponging miR-513a-5p. Frontiers in Oncology. 10. 571565–571565. 20 indexed citations
9.
Jiang, Yiming, et al.. (2020). Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy. Journal of Cancer Research and Clinical Oncology. 147(2). 499–505. 15 indexed citations
10.
Zhang, Pengfei, Xu Pei, Kesang Li, et al.. (2019). Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Molecular Cancer. 18(1). 179–179. 192 indexed citations
11.
12.
Song, Fei, Biao Wang, Kesang Li, et al.. (2018). The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III. Cellular Physiology and Biochemistry. 46(1). 226–237. 12 indexed citations
13.
Chen, Cheng, Kesang Li, Hua Jiang, et al.. (2016). Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunology Immunotherapy. 66(4). 475–489. 82 indexed citations
14.
Li, Zonghai, Cheng Chen, Kesang Li, et al.. (2016). 202. Development of T-Cells Carrying Two Complementary Chimeric Antigen Receptors Against GPC3 and ASGR1 for the Treatment of Hepatocellular Carcinoma. Molecular Therapy. 24. S79–S79. 2 indexed citations
15.
Xu, Wen, Juan Kong, Jiqin Zhang, et al.. (2016). Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN− glioblastoma in vivo. Oncotarget. 7(17). 24752–24765. 13 indexed citations
16.
Xu, Wen, Jiqin Zhang, Juan Kong, et al.. (2015). Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12. Oncotarget. 6(36). 38840–38853. 6 indexed citations
17.
Li, Kesang, Xiaorong Pan, Wen Xu, et al.. (2015). Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget. 7(3). 2496–2507. 32 indexed citations
18.
Gao, Huiping, Kesang Li, Hong Tu, et al.. (2014). Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clinical Cancer Research. 20(24). 6418–6428. 259 indexed citations
19.
Zhou, Min, Hai Wang, Keke Zhou, et al.. (2013). A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells. Cancer Research. 73(23). 7056–7067. 20 indexed citations
20.
Zhang, Pengfei, Bizhi Shi, Huiping Gao, et al.. (2013). An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunology Immunotherapy. 63(2). 121–132. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiuqi Wu Breakdown of academic impact, for papers by Zachary Rae Breakdown of academic impact, for papers by Jizhou Tan Breakdown of academic impact, for papers by Huajun Jin Breakdown of academic impact, for papers by Huiping Gao Breakdown of academic impact, for papers by Christine Alewine Breakdown of academic impact, for papers by Mei‐Kuang Chen Breakdown of academic impact, for papers by Liman Qiu Breakdown of academic impact, for papers by Chang Gon Kim Breakdown of academic impact, for papers by Zhenlong Ye
Rankless by CCL
2026